These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 26951040)

  • 21. Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours.
    Masucci GV; Wersäll P; Kiessling R; Lundqvist A; Lewensohn R
    J Transl Med; 2012 May; 10():104. PubMed ID: 22616654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases.
    Corrao G; Marvaso G; Ferrara R; Lo Russo G; Gugliandolo SG; Piperno G; Spaggiari L; De Marinis F; Orecchia R; Garassino MC; Jereczek-Fossa BA
    Lung Cancer; 2020 Apr; 142():70-79. PubMed ID: 32120227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
    Pico de Coaña Y; Choudhury A; Kiessling R
    Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune checkpoint inhibitors: a new frontier in bladder cancer.
    Kates M; Sopko NA; Matsui H; Drake CG; Hahn NM; Bivalacqua TJ
    World J Urol; 2016 Jan; 34(1):49-55. PubMed ID: 26487055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic ablative body radiotherapy for lung cancer.
    Franks KN; Jain P; Snee MP
    Clin Oncol (R Coll Radiol); 2015 May; 27(5):280-9. PubMed ID: 25746732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction.
    Musunuru HB; Loblaw A
    Future Oncol; 2015; 11(5):819-31. PubMed ID: 25757684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Combination of stereotactic irradiation and chemotherapy or targeted therapies: state of the art and preliminary recommendations].
    Thariat J; Kirova Y; Milano G; Mornex F
    Cancer Radiother; 2014; 18(4):270-9. PubMed ID: 25053603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality.
    Ko EC; Formenti SC
    Int J Radiat Biol; 2019 Jul; 95(7):936-939. PubMed ID: 31120369
    [No Abstract]   [Full Text] [Related]  

  • 30. Current and Emerging Perspectives on Immunotherapy for Melanoma.
    Daud A
    Semin Oncol; 2015 Dec; 42 Suppl 3():S3-S11. PubMed ID: 26598057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Synergy between radiotherapy and immunotherapy in the treatment of advanced malignancies: recent evidences of a new challenge in oncology].
    Corvò R; Belgioia L
    Recenti Prog Med; 2015 Jul; 106(7):322-30. PubMed ID: 26228723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.
    Blank CU
    Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?
    Siva S; Slotman BJ
    Semin Radiat Oncol; 2017 Jul; 27(3):229-239. PubMed ID: 28577830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The immune checkpoint inhibitors: where are we now?
    Webster RM
    Nat Rev Drug Discov; 2014 Dec; 13(12):883-4. PubMed ID: 25345674
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 2: Existing Experience and Considerations for Future Trials.
    Zhang I; Formenti SC; Knisely JPS
    Oncology (Williston Park); 2018 Mar; 32(3):e33-e37. PubMed ID: 29548066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expanding role of immunotherapy.
    Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J
    Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereotactic ablative radiotherapy in treatment of early-stage non-small cell lung cancer: Unsolved questions and frontiers ahead.
    Zhang J; Kong L; Jiao Q; Li M; Yu J
    Cancer Lett; 2017 Aug; 401():46-52. PubMed ID: 28526616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining radiotherapy and immunotherapy: a revived partnership.
    Demaria S; Bhardwaj N; McBride WH; Formenti SC
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):655-66. PubMed ID: 16199306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.
    Siva S; Kothari G; Muacevic A; Louie AV; Slotman BJ; Teh BS; Lo SS
    Nat Rev Urol; 2017 Sep; 14(9):549-563. PubMed ID: 28631740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.